This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Now that 2020 is in the rear view mirror, most of us are ready to bid good riddance to an incredibly tumultuous year and do our best to forget it. But before you barrel ahead into 2021 and look for signs of returning to the “good old days,” sales leaders and their teams have a lot to learn from 2020.
Many sales influencers are doing great things, but we wanted to shine a spotlight on a few of our favorites, those whose viewpoints align well with ours and can help motivate you and your teams to perform better in 2020. . The post Our 10 (OK, 11) Favorite Sales Influencers of 2020 appeared first on Integrity Solutions.
Sales Enablement Strategy: 2020 vs. 2019. The post Adapting Your Sales Enablement Strategy to 2020 Realities appeared first on Integrity Solutions. So then what should sales enablement strategy mean, particularly now, and how can it help your sales team deal with the specific challenges of this current selling environment?
in 2020, the report found. Overall spending by employers and employees on mental health services as a percentage of total spending rose from 6.8% in 2013 to 8.2% The use of the mental health services also increased, especially in outpatient settings.
Is your team focused on building a reliable tech stack for 2020? Forward thinking sales leaders are starting to prioritize technology initiatives. As organizations chase new revenue targets, B2B sales leaders must examine cutting edge prospecting solutions that proactively help reps identify, connect with, and close qualified buyers faster.
For most of us, 2020 is a year we’ll be glad to see in the rear-view mirror. While disruption is always rough when you’re going through it, as 2020 closes out, we can also reflect back on some of the silver linings and positive developments that came out of the year.
Whatever IT Takes Mentality For Candidates In 2020 Whatever IT Takes Mentality For Medical Device Sales Candidates In 2020 The 2020 theme for candidates trying to break into the medical device sales industry is going to be whatever it takes for more on this let’s break everything down.
Now, the manufacturing arriviste—which was founded in 2020—is expanding its production network again with the acquisition of Switzerland's Baccinex, which specializes in fill and finish services.
After an initial rejection in 2020 and a review delay earlier this year, BioMarin’s Roctavian has finally got the FDA go-ahead to introduce a gene therapy for a not-so-rare disorder.
This report aims to highlight the current state of B2B database and contact acquisition strategies and organizations’ goals to leverage data to fuel their go-to-market strategies in 2020 and beyond.
It was 2020 and Maryland biotech Novavax was thinking big. Novavax purchased the site in May of 2020 for $167 million with the intent of it producing more than 1 billion doses annually there. Novavax purchased the site in May of 2020 for $167 million with the intent of it producing more than 1 billion doses annually there.
In just 2020, deaths from gun violence cost the U.S. healthcare system $290 million, or about $6,400 per patient, according to a report from the Commonwealth Fund. These costs are mostly covered by Medicaid and other government insurance programs.
Discover valuable insights and practical steps on how to: Adjust your tactics to deal with the impact of 2020. If your role includes supporting sellers, then this in-depth sales enablement guide is for you! Keep remote onboarding and training engaging (including SKO). Deliver content and tools sellers will love.
Medical IoT is forecast to grow from $41 billion in 2020 to $188 billion by 2028. The growth is for a good reason: Connected medical devices, combined with the right software, can improve conditions and delivery, optimize care and devices, and save lives.
billion acquisition of Dermira in 2020. Eli Lilly drug Ebglyss is now FDA-approved for atopic dermatitis, an inflammatory skin disorder also known as eczema. The biologic drug came from Lilly’s $1.1 The post New Eli Lilly Eczema Drug Brings Competition and Dosing Edge Versus Sanofi, LEO Pharma Meds appeared first on MedCity News.
SR One’s new investment fund is its second one since spinning out of GSK in 2020. The firm says it now has more than $1.5 billion in assets under management.
Roche's spinal muscular atrophy (SMA) medicine Evrysdi only gained its FDA approval in 2020, but generics companies are already eying the blockbuster as a potential target. | The spinal muscular atrophy drug is a growth driver for the Swiss pharma giant, prompting the company to prioritize its defense against potential generics.
GPA in 2022, a slight decrease from Leapfrog’s prior survey in 2020, which had a 2.57 From those letter grades, Leapfrog calculated the health plans’ average Grade Point Average (GPA) on a 4.0 Health plans received a 2.29
Approval of Akebia Therapeutics’ Vafseo is based on additional post-marketing safety data from Japan, where the drug has been used since 2020. The FDA rejected the drug two years ago due to concerns about cardiovascular safety.
But this Phase 2 failure follows the 2020 clinical trial pause of a different partnered molecule that addresses the same target. Sanofi, which is leading development of the Denali Therapeutics-partnered molecule, disclosed little about the clinical trial results in ALS.
The deal follows another acquisition WebMD made in the patient engagement space in 2020. WebMD acquired the operating assets of Healthwise, a nonprofit provider of health education content and patient engagement tools.
Pregnancy-related complications increased 9% between 2018 and 2020 among all women, but the rate of change is even more significant among women of color. The disparities exist regardless of having commercial insurance or Medicaid.
commercial rollout of the company’s implantable device, which received FDA de novo clearance in 2020. Miach Orthopaedics — a medical device company focused on restoring torn ACLs instead of reconstructing them — recently received $40 million in funding. The capital will be used to expand the U.S.
They said it’s important to remember that the mega-boom of 2020 and 2021 was an anomaly for the sector. Digital health’s Q3 saw the lowest quarterly funding total in the past 11 quarters, but experts don’t think this trend should be a cause for concern.
It’s also the first medicine using the revolutionary CRISPR gene-editing system, which earned its inventors a Nobel Prize in 2020 and holds tantalizing potential to cure diseases for which there is no treatment.
Elizabeth Mily, who replaced BMS’ former M&A czar Paul Biondi back in 2020, is headed for the exit, the company confirmed Friday. Three years on, Bristol Myers Squibb is bidding adieu to its top dealmaker. Three years on, Bristol Myers Squibb is bidding adieu to its top dealmaker.
from 2020 to 2021. EmpiRx found in its data that pharmacy claims for behavioral health treatments increased 9.4% For antidepressants, utilization increased 12% during this time period, but per claim spend fell 1.8%. ADHD medications saw a 20.2% increase in utilization and a 9.1% decrease in per claim spend.
Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated multiple myeloma. Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated multiple myeloma. That changed Friday. That changed Friday.
The FDA refused to accept Supernus' first approval bid after the company acquired the med in 2020. The third time is decidedly not the charm for Supernus and its Parkinson’s disease infusion pump. | The following year, the agency doled out a complete response letter, dashing Supernus' second try.
But in 2020, 2021 and 2022, enrollment rose by 1.9 Enrollment in Medicare Advantage plans increased by 5.5% this year, or by 1.5 million beneficiaries, according to The Chartis Group. million, 2.2 million and 2.3 million, respectively.
For more than three-quarters of these hospitals, their spending on charity care and community investment was less than the money they received in tax breaks in 2020. A new report from Lown Institute examined the finances of 1,773 private nonprofit hospitals across the U.S. These combined deficits totaled $14.2
From 2016 to 2020, the 14 leading drug companies spent $577 billion on stock buybacks and dividends—$56 billion more than they spent on R&D over the same period.” ” From 2016 to 2020, compensation for the 14 companies’ top executives totaled $3.2 The drug industry is driven by profits, not by patient’s needs.
According to data from KFF’s annual survey of employers , between 2010 and 2020, insurance premiums for employer-sponsored family coverage rose by 55 percent; the employer’s contribution went up 61 percent. On a percentage basis, the figure for 2020 was Independence’s highest profit margin since 2011, records show.
The loss of patent protection on Amarin’s sole commercial product Vascepa in 2020 has led to a roller coaster ride for the Dublin-based company over the past few years. Amarin is getting a fresh shot to challenge Hikma Pharmaceuticals’ generic version of its fish oil-derived heart med in the lower courts. business.
ReKlame Health launched in 2020 to provide affordable, culturally competent behavioral healthcare to Black and Brown communities in New York. On Monday, the startup announced it is now serving patients in two additional states — New Jersey and Florida.
In 2020, 46.9% of all novel drugs approved by the FDA were for rare diseases, as compared to 23.5% Investment is expected to continue trending upward, with estimates suggesting that global spending on rare disease therapies will reach $260 billion by the end of 2025.
It’s been 15 years since Genzyme began rationing the Fabry disease treatment Fabrazyme after a shortage caused by contamination at a manufacturing site, marking the start of many years of litigatio | Sanofi's Genzyme was accused of causing injuries after contaminated doses of its Fabry disease drug led to a shortage, during which the company rationed (..)
The 2020-approved breast cancer med booked $17.9 MacroGenics’ first commercial product, breast cancer drug Margenza, is heading off to TerSera Therapeutics through a $40 million hand-off. | million in 2023 sales as it struggled to make a mark in the crowded market.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content